董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Paul R. Gudonis | 男 | President, Chief Executive Officer and Chairman of the Board | 72 | 120.12万美元 | 111.53 | 2026-06-25 |
| Thomas A. Crowley | 男 | Independent Director | 79 | 14.75万美元 | 7.61 | 2026-06-25 |
| Joseph M. Manko, Jr. | 男 | Independent Director | 60 | 未披露 | 210.86 | 2026-06-25 |
| Milton M. Morris | 男 | Independent Director | 56 | 14.75万美元 | 14.47 | 2026-06-25 |
| Joseph M. Manko, Jr. | 男 | Independent Director | 60 | 未披露 | 未持股 | 2026-06-25 |
| William J. Febbo | 男 | Independent Director | 57 | 未披露 | 未持股 | 2026-06-25 |
| Thomas F. Kirk | 男 | Lead Independent Director | 80 | 14.75万美元 | 55.42 | 2026-06-25 |
| Heather C. Getz | 女 | Independent Director | 51 | 14.75万美元 | 13.18 | 2026-06-25 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Paul R. Gudonis | 男 | President, Chief Executive Officer and Chairman of the Board | 72 | 120.12万美元 | 111.53 | 2026-06-25 |
| Micah J. Mitchell | 男 | Chief Commercial Officer | 50 | 未披露 | 未持股 | 2026-06-25 |
| Harry Kovelman | 男 | Chief Medical Officer | 67 | 60.78万美元 | 8.60 | 2026-06-25 |
| David A. Henry | 男 | Chief Financial Officer | 64 | 69.02万美元 | 36.01 | 2026-06-25 |
董事简历
中英对照 | 中文 | 英文- Paul R. Gudonis
-
PaulR.Gudonis自2016年8月以来一直担任我们的董事会主席，自2011年7月以来担任我们的首席执行官兼董事。Gudonis先生也于2017年2月被任命为总裁。他的职业生涯横跨软件、电信、互联网服务和机器人领域。加入公司之前，Gudonis从2005年10月到2010年6月担任First Robotics总裁。在开始担任该职位之前，从2003年8月到2005年4月，Gudonis先生是Centra Software，Inc.的首席执行官。从2000年1月到2003年3月，Gudonis先生还担任Genuity，Inc.的首席执行官。他也曾担任马萨诸塞州高科技委员会主席，他是他的母校西北大学麦考密克工程学院院长顾问委员会的成员，在那里他获得了电气工程学位。在学校，他在生物医学工程系和NuVention医疗器械创新计划的顾问委员会任职。他还获得了Harvard University的工商管理硕士学位。
Paul R. Gudonis has been the Chairman of Myomo, Inc.'s board of directors since August 2016 and Myomo, Inc.'s Chief Executive Officer and a director of Myomo, Inc.'s company since July 2011. Mr. Gudonis was also appointed President in February 2017. During his tenure at Myomo, he has grown Myomo, Inc.'s operations, obtained reimbursement of the MyoPro by Medicare and other payers in the United States, and has expanded Myomo, Inc.'s business internationally. He has 40 years of experience in launching new technology based products and services to Myomo, Inc.'s company. His career spans the fields of software, telecommunications, internet services, and robotics. Prior to joining Myomo, Inc.'s company, Mr. Gudonis served as President at FIRST Robotics, or FIRST, from October 2005 until June 2010. Prior to his position at FIRST, Mr. Gudonis was the Chief Executive Officer of Centra Software, Inc., from August 2003 until April 2005. Mr. Gudonis was also the Chief Executive Officer of Genuity, Inc. from January 2000 until March 2003. He has also served as Chairman of the Massachusetts High Tech Council. Mr. Gudonis is a member of the Dean's Advisory Council at his alma mater, Northwestern University's McCormick School of Engineering, where he earned his degree in electrical engineering. At McCormick, he also serves on the industry advisory board of the Biomedical Engineering Department. He earned his MBA degree from Harvard University. - PaulR.Gudonis自2016年8月以来一直担任我们的董事会主席，自2011年7月以来担任我们的首席执行官兼董事。Gudonis先生也于2017年2月被任命为总裁。他的职业生涯横跨软件、电信、互联网服务和机器人领域。加入公司之前，Gudonis从2005年10月到2010年6月担任First Robotics总裁。在开始担任该职位之前，从2003年8月到2005年4月，Gudonis先生是Centra Software，Inc.的首席执行官。从2000年1月到2003年3月，Gudonis先生还担任Genuity，Inc.的首席执行官。他也曾担任马萨诸塞州高科技委员会主席，他是他的母校西北大学麦考密克工程学院院长顾问委员会的成员，在那里他获得了电气工程学位。在学校，他在生物医学工程系和NuVention医疗器械创新计划的顾问委员会任职。他还获得了Harvard University的工商管理硕士学位。
- Paul R. Gudonis has been the Chairman of Myomo, Inc.'s board of directors since August 2016 and Myomo, Inc.'s Chief Executive Officer and a director of Myomo, Inc.'s company since July 2011. Mr. Gudonis was also appointed President in February 2017. During his tenure at Myomo, he has grown Myomo, Inc.'s operations, obtained reimbursement of the MyoPro by Medicare and other payers in the United States, and has expanded Myomo, Inc.'s business internationally. He has 40 years of experience in launching new technology based products and services to Myomo, Inc.'s company. His career spans the fields of software, telecommunications, internet services, and robotics. Prior to joining Myomo, Inc.'s company, Mr. Gudonis served as President at FIRST Robotics, or FIRST, from October 2005 until June 2010. Prior to his position at FIRST, Mr. Gudonis was the Chief Executive Officer of Centra Software, Inc., from August 2003 until April 2005. Mr. Gudonis was also the Chief Executive Officer of Genuity, Inc. from January 2000 until March 2003. He has also served as Chairman of the Massachusetts High Tech Council. Mr. Gudonis is a member of the Dean's Advisory Council at his alma mater, Northwestern University's McCormick School of Engineering, where he earned his degree in electrical engineering. At McCormick, he also serves on the industry advisory board of the Biomedical Engineering Department. He earned his MBA degree from Harvard University.
- Thomas A. Crowley
-
ThomasA.Crowley，Jr.自2012年3月以来一直是我们的董事会成员。Crowley先生自2011年7月起担任Vertical Spine，LLC的董事会成员。他也曾任职Cascade Medical Enterprises，LLC的董事会（2008年1月以来）。他积极从事为四家医疗器械公司和两家私募股权公司提供治理和商业建议，涉及金融交易、商业战略和执行。他还从2011年3月到2012年3月担任Core Essence Orthopedics，Inc.董事长。Crowley先生曾是Aircast的董事会成员，2003年9月至2006年5月担任LLC，2011年3月至2013年6月担任and Freedom Innovations的董事会成员，2010年1月和2011年12月分别担任Corporate Advisory Council和American Society for Surgery of the Hand的成员。担任现任职务之前，Crowley从2008年2月到2011年2月担任Small Bone Innovations，Inc.总裁。2006年9月至2008年1月，他还担任Friedman Billings Ramsey的梦百合投资银行总经理。Crowley先生拥有费尔菲尔德大学（Fairfield University）的学士学位，哥伦比亚大学商学院（Columbia University School of Business）的硕士学位，并且是堪萨斯州莱文沃思堡美国陆军指挥和总参谋部学院（U.S.Army Command General Staff College）毕业生。
Thomas A. Crowley has been a member of Myomo, Inc.'s board of directors since March 2012. Mr. Crowley retired as Chief Executive Officer of Vertical Spine, LLC in 2025 and served on its board of directors from 2011 to 2025. He also served on the board of Cascade Medical Enterprises, LLC from January 2008 to January 2020, as Chairman of Core Essence Orthopedics, Inc. from March 2011 until March 2012, as President and board member of Aircast, LLC from September 2003 until May 2006 and as a board member of Freedom Innovations from March 2011 until June 2013. Additionally, Mr. Crowley served as member of the Corporate Advisory Council of the American Society for Surgery of the Hand from November 2004 to May 2006. Mr. Crowley was President of Small Bone Innovations, Inc. from February 2008 until February 2011. He also served as Managing Director—Healthcare Investment Banking at Friedman Billings Ramsey from September 2006 until January 2008. Mr. Crowley holds a BA from Fairfield University, an MS from Columbia University School of Business and is a Graduate, U.S. Army Command and General Staff College, Ft. Leavenworth, KS. - ThomasA.Crowley，Jr.自2012年3月以来一直是我们的董事会成员。Crowley先生自2011年7月起担任Vertical Spine，LLC的董事会成员。他也曾任职Cascade Medical Enterprises，LLC的董事会（2008年1月以来）。他积极从事为四家医疗器械公司和两家私募股权公司提供治理和商业建议，涉及金融交易、商业战略和执行。他还从2011年3月到2012年3月担任Core Essence Orthopedics，Inc.董事长。Crowley先生曾是Aircast的董事会成员，2003年9月至2006年5月担任LLC，2011年3月至2013年6月担任and Freedom Innovations的董事会成员，2010年1月和2011年12月分别担任Corporate Advisory Council和American Society for Surgery of the Hand的成员。担任现任职务之前，Crowley从2008年2月到2011年2月担任Small Bone Innovations，Inc.总裁。2006年9月至2008年1月，他还担任Friedman Billings Ramsey的梦百合投资银行总经理。Crowley先生拥有费尔菲尔德大学（Fairfield University）的学士学位，哥伦比亚大学商学院（Columbia University School of Business）的硕士学位，并且是堪萨斯州莱文沃思堡美国陆军指挥和总参谋部学院（U.S.Army Command General Staff College）毕业生。
- Thomas A. Crowley has been a member of Myomo, Inc.'s board of directors since March 2012. Mr. Crowley retired as Chief Executive Officer of Vertical Spine, LLC in 2025 and served on its board of directors from 2011 to 2025. He also served on the board of Cascade Medical Enterprises, LLC from January 2008 to January 2020, as Chairman of Core Essence Orthopedics, Inc. from March 2011 until March 2012, as President and board member of Aircast, LLC from September 2003 until May 2006 and as a board member of Freedom Innovations from March 2011 until June 2013. Additionally, Mr. Crowley served as member of the Corporate Advisory Council of the American Society for Surgery of the Hand from November 2004 to May 2006. Mr. Crowley was President of Small Bone Innovations, Inc. from February 2008 until February 2011. He also served as Managing Director—Healthcare Investment Banking at Friedman Billings Ramsey from September 2006 until January 2008. Mr. Crowley holds a BA from Fairfield University, an MS from Columbia University School of Business and is a Graduate, U.S. Army Command and General Staff College, Ft. Leavenworth, KS.
- Joseph M. Manko, Jr.
-
JosephM.Manko，Jr.自2013年以来一直担任Horton Capital Management LLC的高级负责人，Horton Capital Partners Fund，LP“Horton Fund”的投资经理。霍顿基金是该公司的重要股东。Manko先生在资产管理、投资银行、私募股权和企业证券市场拥有超过20年的投资经验。从2005年到2010年，他曾担任BZ Fund Management Limited（位于瑞士）的合伙人兼首席执行官，在那里他曾负责公司财务、私人股本投资、三个公共股本基金和公司的特殊情况和事件驱动战略。在此之前，Manko先生是伦敦Deutsche Bank的董事总经理。他的投资银行生涯始于美林证券（Merrill Lynch），担任香港Vice President，在此之前，Manko先生是Skadden，Arps，Slate，Meagher&Flom LLP的公司财务律师。Manko先生曾在生物制药行业的几家公司的董事会任职，并为制药、生物技术和医疗技术行业的许多公司提供建议，目前担任SafeguardScientifics，Inc.、Wireless TelecomGroup，Inc.和CreativeRealities，Inc.的董事。Manko先生在宾夕法尼亚大学（University of Pennsylvania）获得学士学位和法学博士学位。
Joseph M. Manko, Jr. has been the Senior Principal in Horton Capital Management LLC, the investment manager for the Horton Capital Partners Fund, LP "Horton Fund" since 2013. The Horton Fund is a significant shareholder in the Company. Mr. Manko has over 20 years of investment experience in the asset management, investment banking, private equity and corporate securities markets. From 2005 to 2010 Mr. Manko was a Partner and Chief Executive Officer of Switzerland-based BZ Fund Management Limited, where he was responsible for corporate finance, private equity investments, three public equity funds and the firm's Special Situations and Event-Driven strategies. Prior to that Mr. Manko was a Managing Director with Deutsche Bank in London. He began his investment banking career at Merrill Lynch as a Vice President in Hong Kong and prior to that, Mr. Manko was a corporate finance attorney at Skadden, Arps, Slate, Meagher & Flom LLP. Mr. Manko has served on the board of several companies in the bio-pharmaceutical industry and has advised numerous companies in the pharmaceutical, biotech and medtech industries and currently serves as a director of Safeguard Scientifics, Inc., Wireless Telecom Group, Inc., and Creative Realities, Inc. Mr. Manko earned both his B.A. and Juris Doctor from the University of Pennsylvania. - JosephM.Manko，Jr.自2013年以来一直担任Horton Capital Management LLC的高级负责人，Horton Capital Partners Fund，LP“Horton Fund”的投资经理。霍顿基金是该公司的重要股东。Manko先生在资产管理、投资银行、私募股权和企业证券市场拥有超过20年的投资经验。从2005年到2010年，他曾担任BZ Fund Management Limited（位于瑞士）的合伙人兼首席执行官，在那里他曾负责公司财务、私人股本投资、三个公共股本基金和公司的特殊情况和事件驱动战略。在此之前，Manko先生是伦敦Deutsche Bank的董事总经理。他的投资银行生涯始于美林证券（Merrill Lynch），担任香港Vice President，在此之前，Manko先生是Skadden，Arps，Slate，Meagher&Flom LLP的公司财务律师。Manko先生曾在生物制药行业的几家公司的董事会任职，并为制药、生物技术和医疗技术行业的许多公司提供建议，目前担任SafeguardScientifics，Inc.、Wireless TelecomGroup，Inc.和CreativeRealities，Inc.的董事。Manko先生在宾夕法尼亚大学（University of Pennsylvania）获得学士学位和法学博士学位。
- Joseph M. Manko, Jr. has been the Senior Principal in Horton Capital Management LLC, the investment manager for the Horton Capital Partners Fund, LP "Horton Fund" since 2013. The Horton Fund is a significant shareholder in the Company. Mr. Manko has over 20 years of investment experience in the asset management, investment banking, private equity and corporate securities markets. From 2005 to 2010 Mr. Manko was a Partner and Chief Executive Officer of Switzerland-based BZ Fund Management Limited, where he was responsible for corporate finance, private equity investments, three public equity funds and the firm's Special Situations and Event-Driven strategies. Prior to that Mr. Manko was a Managing Director with Deutsche Bank in London. He began his investment banking career at Merrill Lynch as a Vice President in Hong Kong and prior to that, Mr. Manko was a corporate finance attorney at Skadden, Arps, Slate, Meagher & Flom LLP. Mr. Manko has served on the board of several companies in the bio-pharmaceutical industry and has advised numerous companies in the pharmaceutical, biotech and medtech industries and currently serves as a director of Safeguard Scientifics, Inc., Wireless Telecom Group, Inc., and Creative Realities, Inc. Mr. Manko earned both his B.A. and Juris Doctor from the University of Pennsylvania.
- Milton M. Morris
-
Milton M. Morris自2021年6月起担任Myomo, Inc.董事会成员。莫里斯博士也是国家公司董事协会（NACD）董事认证TM，目前作为顾问服务于公共和私营公司。Morris博士自2022年3月起担任Embecta Corp.的董事会成员，自2022年9月起担任Nordson Corp.的董事会成员。Morris博士被评为30多项专利的发明人，以及20份同行评审出版物、书籍章节、摘要和科学报告的作者。莫里斯博士是西北大学的受托人，也是美国医学和生物工程研究所（AIMBE）的研究员，他因在生物电子医学创新的开发和商业化方面的贡献而入选。Morris博士获得了家乐氏管理学院的MBA学位、密歇根大学的电气工程学硕士和博士学位以及西北大学的电气工程学理学学士学位。
Milton M. Morris is also National Association of Corporate Directors (NACD) Directorship CertifiedTM and currently serves both public and private companies as a consultant. Dr. Morris has served on the board of directors of Embecta Corp. since March 2022 and Nordson Corp. since September 2022.Prior to joining Guidant, Dr. Morris spent five years working as a Research Assistant in the Medical Computing Laboratory at the University of Michigan in collaboration with the electrophysiology group at the University of Michigan hospital and the Michigan Heart and Vascular Institute. During this period, Dr. Morris was awarded fellowships from the National Science Foundation (NSF) and the National Institutes of Health (NIH) in support of his research on the development of novel approaches to low power arrhythmia classification algorithms designed for implantable defibrillators. Dr. Morris is named as an inventor on over 30 patents and an author on 20 peer reviewed publications, book chapters, abstracts and scientific presentations. Dr. Morris serves as a Trustee for Northwestern University and as a Fellow in the American Institute for Medical and Biological Engineering (AIMBE) where he was inducted for contributions to developing and commercializing innovations in bioelectronic medicine. Dr. Morris received an MBA from the Kellogg School of Management, a Masters and Ph.D. in Electrical Engineering from the University of Michigan and a Bachelor of Science in Electrical Engineering from Northwestern University. - Milton M. Morris自2021年6月起担任Myomo, Inc.董事会成员。莫里斯博士也是国家公司董事协会（NACD）董事认证TM，目前作为顾问服务于公共和私营公司。Morris博士自2022年3月起担任Embecta Corp.的董事会成员，自2022年9月起担任Nordson Corp.的董事会成员。Morris博士被评为30多项专利的发明人，以及20份同行评审出版物、书籍章节、摘要和科学报告的作者。莫里斯博士是西北大学的受托人，也是美国医学和生物工程研究所（AIMBE）的研究员，他因在生物电子医学创新的开发和商业化方面的贡献而入选。Morris博士获得了家乐氏管理学院的MBA学位、密歇根大学的电气工程学硕士和博士学位以及西北大学的电气工程学理学学士学位。
- Milton M. Morris is also National Association of Corporate Directors (NACD) Directorship CertifiedTM and currently serves both public and private companies as a consultant. Dr. Morris has served on the board of directors of Embecta Corp. since March 2022 and Nordson Corp. since September 2022.Prior to joining Guidant, Dr. Morris spent five years working as a Research Assistant in the Medical Computing Laboratory at the University of Michigan in collaboration with the electrophysiology group at the University of Michigan hospital and the Michigan Heart and Vascular Institute. During this period, Dr. Morris was awarded fellowships from the National Science Foundation (NSF) and the National Institutes of Health (NIH) in support of his research on the development of novel approaches to low power arrhythmia classification algorithms designed for implantable defibrillators. Dr. Morris is named as an inventor on over 30 patents and an author on 20 peer reviewed publications, book chapters, abstracts and scientific presentations. Dr. Morris serves as a Trustee for Northwestern University and as a Fellow in the American Institute for Medical and Biological Engineering (AIMBE) where he was inducted for contributions to developing and commercializing innovations in bioelectronic medicine. Dr. Morris received an MBA from the Kellogg School of Management, a Masters and Ph.D. in Electrical Engineering from the University of Michigan and a Bachelor of Science in Electrical Engineering from Northwestern University.
- Joseph M. Manko, Jr.
-
Joseph M. Manko，Jr.自2013年以来一直担任Horton Capital Management LLC的高级负责人，该公司是Horton Capital Partners Fund，LP（“Horton Fund”）的投资经理。霍顿基金是该公司的重要股东。Manko先生在资产管理、投资银行、私募股权和公司证券市场拥有超过25年的投资经验。从2005年到2010年，Manko先生是瑞士BZ基金管理有限公司的合伙人兼首席执行官，负责公司融资、私募股权投资、三大公募基金以及公司的特殊情况和事件驱动战略。在此之前，Manko先生是伦敦德意志银行的董事总经理。他在美林证券开始了他的投资银行职业生涯，担任香港副总裁，在此之前，Manko先生是Skadden，Arps，Slate，Meagher & Flom LLP的企业融资律师。Manko先生曾在医疗技术和生物制药行业的多家公司的董事会任职，曾为制药、生物技术和医疗技术行业的多家公司提供咨询服务。他目前担任安科投资公司的董事和董事长以及KORU医疗系统公司的董事，之前还曾担任Wireless Telecom Group, Inc.、One Stop Systems, Inc.和Creative Realities, Inc.的董事。Manko先生在宾夕法尼亚大学获得了学士学位和法学博士学位。
Joseph M. Manko, Jr. has been the Senior Principal in Horton Capital Management LLC, the investment manager for the Horton Capital Partners Fund, LP ("Horton Fund") since 2013. The Horton Fund is a significant shareholder in the Company. Mr. Manko has over 25 years of investment experience in the asset management, investment banking, private equity and corporate securities markets. From 2005 to 2010, Mr. Manko was a Partner and Chief Executive Officer of Switzerland based BZ Fund Management Limited, where he was responsible for corporate finance, private equity investments, three public equity funds and the firm's Special Situations and Event Driven strategies. Prior to that Mr. Manko was a Managing Director with Deutsche Bank in London. He began his investment banking career at Merrill Lynch as a Vice President in Hong Kong and prior to that, Mr. Manko was a corporate finance attorney at Skadden, Arps, Slate, Meagher & Flom LLP. Mr. Manko has served on the board of several companies in the med tech and bio pharmaceutical industry and has advised numerous companies in the pharmaceutical, biotech and medtech industries and currently serves as a director and Chairman of Safeguard Scientifics, Inc. and director of KORU Medical Systems, Inc. and previously served as a director of Wireless Telecom Group, Inc., One Stop Systems, Inc., and Creative Realities, Inc. Mr. Manko earned both his B.A. and Juris Doctor from the University of Pennsylvania. - Joseph M. Manko，Jr.自2013年以来一直担任Horton Capital Management LLC的高级负责人，该公司是Horton Capital Partners Fund，LP（“Horton Fund”）的投资经理。霍顿基金是该公司的重要股东。Manko先生在资产管理、投资银行、私募股权和公司证券市场拥有超过25年的投资经验。从2005年到2010年，Manko先生是瑞士BZ基金管理有限公司的合伙人兼首席执行官，负责公司融资、私募股权投资、三大公募基金以及公司的特殊情况和事件驱动战略。在此之前，Manko先生是伦敦德意志银行的董事总经理。他在美林证券开始了他的投资银行职业生涯，担任香港副总裁，在此之前，Manko先生是Skadden，Arps，Slate，Meagher & Flom LLP的企业融资律师。Manko先生曾在医疗技术和生物制药行业的多家公司的董事会任职，曾为制药、生物技术和医疗技术行业的多家公司提供咨询服务。他目前担任安科投资公司的董事和董事长以及KORU医疗系统公司的董事，之前还曾担任Wireless Telecom Group, Inc.、One Stop Systems, Inc.和Creative Realities, Inc.的董事。Manko先生在宾夕法尼亚大学获得了学士学位和法学博士学位。
- Joseph M. Manko, Jr. has been the Senior Principal in Horton Capital Management LLC, the investment manager for the Horton Capital Partners Fund, LP ("Horton Fund") since 2013. The Horton Fund is a significant shareholder in the Company. Mr. Manko has over 25 years of investment experience in the asset management, investment banking, private equity and corporate securities markets. From 2005 to 2010, Mr. Manko was a Partner and Chief Executive Officer of Switzerland based BZ Fund Management Limited, where he was responsible for corporate finance, private equity investments, three public equity funds and the firm's Special Situations and Event Driven strategies. Prior to that Mr. Manko was a Managing Director with Deutsche Bank in London. He began his investment banking career at Merrill Lynch as a Vice President in Hong Kong and prior to that, Mr. Manko was a corporate finance attorney at Skadden, Arps, Slate, Meagher & Flom LLP. Mr. Manko has served on the board of several companies in the med tech and bio pharmaceutical industry and has advised numerous companies in the pharmaceutical, biotech and medtech industries and currently serves as a director and Chairman of Safeguard Scientifics, Inc. and director of KORU Medical Systems, Inc. and previously served as a director of Wireless Telecom Group, Inc., One Stop Systems, Inc., and Creative Realities, Inc. Mr. Manko earned both his B.A. and Juris Doctor from the University of Pennsylvania.
- William J. Febbo
-
WilliamJ.Febbo于2016年2月22日加入本公司，担任首席执行官兼董事。在加入我们公司之前。从2007年到2015年，他在投资银行公司MerrimanHoldings，Inc.工作。在那里他曾担任首席运营官，并协助技术、生物技术、清洁技术、消费者和资源行业的资本筹集。在Merriman之前，Febbo先生是MedPanel的首席执行官兼联合创始人，MedPanel是一家为制药，生物医学和医疗器械行业提供市场情报和通信的提供商，该公司最终被MCF Corporation收购。
William J. Febbo currently serves as Chief Executive Officer and Director of Performance Health Systems, a privately held company that utilizes health and wellness equipment to improve mobility for people at home, businesses, and clinics, which he joined in February 2026. Previously, he served as Chief Executive Officer of OptimizeRx Corporation (NASDAQ: OPRX) from 2015 to 2024, where he transformed the company from a single point of care product provider into an AI driven omnichannel platform. Under his leadership, revenue grew from $5 million to $92 million, achieving a five year CAGR of 41%. He also led OptimizeRx's uplisting from OTC to Nasdaq and expanded its digital healthcare network, contributing to significant growth in its market capitalization. Mr. Febbo has also co founded and led companies focused on the capital markets, including Merriman Holdings, Inc., and Digital Capital Network. Mr. Febbo received a BA in International Studies and Spanish from Dickinson College. He is an MIT affiliated faculty member and mentor in the linQ program, supporting biomedical innovations addressing major health and medical challenges. He also in a Mentor for the X & Y Class at Harvard Business School. - WilliamJ.Febbo于2016年2月22日加入本公司，担任首席执行官兼董事。在加入我们公司之前。从2007年到2015年，他在投资银行公司MerrimanHoldings，Inc.工作。在那里他曾担任首席运营官，并协助技术、生物技术、清洁技术、消费者和资源行业的资本筹集。在Merriman之前，Febbo先生是MedPanel的首席执行官兼联合创始人，MedPanel是一家为制药，生物医学和医疗器械行业提供市场情报和通信的提供商，该公司最终被MCF Corporation收购。
- William J. Febbo currently serves as Chief Executive Officer and Director of Performance Health Systems, a privately held company that utilizes health and wellness equipment to improve mobility for people at home, businesses, and clinics, which he joined in February 2026. Previously, he served as Chief Executive Officer of OptimizeRx Corporation (NASDAQ: OPRX) from 2015 to 2024, where he transformed the company from a single point of care product provider into an AI driven omnichannel platform. Under his leadership, revenue grew from $5 million to $92 million, achieving a five year CAGR of 41%. He also led OptimizeRx's uplisting from OTC to Nasdaq and expanded its digital healthcare network, contributing to significant growth in its market capitalization. Mr. Febbo has also co founded and led companies focused on the capital markets, including Merriman Holdings, Inc., and Digital Capital Network. Mr. Febbo received a BA in International Studies and Spanish from Dickinson College. He is an MIT affiliated faculty member and mentor in the linQ program, supporting biomedical innovations addressing major health and medical challenges. He also in a Mentor for the X & Y Class at Harvard Business School.
- Thomas F. Kirk
-
Thomas F. Kirk， 2008年3月到2012年5月担任公司首席执行官；2002年1月到2011年9月担任公司总裁。2002年1月到2008年2月担任公司首席运营官。现任美国矫形器和假肢协会总裁，这是个志愿者职位。从1998年9月到2002年1月担任AlixPartners有限责任公司（前身是Jay Alix & Associates有限公司，一家管理咨询公司， Hanger 公司保留下来以促进其重组进程）主要负责人。从1997年5月到1998年8月担任FPL Group集团（位于美国佛罗里达州的一家提供全方位服务的能源供应商）规划、发展和质量副总裁。从1996年4月到1997年4月担任宾夕法尼亚州Quaker Chemical Corporation总裁和首席运营官。从1987年12月到1996年3月担任多个职位，最近的职位是担任Rhone Poulenc, S.A.新泽西州普林斯顿和法国巴黎区高级副总裁和首席财务官。从1977年3月到1988年11月在St. Joe Minerals Corp公司（Fluor Corporation公司的一个分部）工作。在此之前，他在Koppers Co有限公司担任多个销售、商业发展和工程职位。他持有美国匹兹堡大学战略规划/营销博士学位以及工商管理金融硕士学位。他还持有卡内基·梅隆大学机械工程学士学位。他是一名注册专业工程师和金融执行协会成员。
Thomas F. Kirk has served as a member of Myomo, Inc.'s board of directors since September 2014 and as Lead Independent Director since October 2016. Mr. Kirk is a seasoned healthcare executive with extensive experience leading growth, operational transformation, and strategic expansion across medical services and device organizations. He most recently served as Chairman and Chief Executive Officer of American Medical Staffing, Inc. from 2013 to 2024, where he led the company's significant growth by expanding into additional clinical specialties, broadening its base of healthcare and rehabilitation customers, and executing on geographic expansion, third party reimbursement strategies, and strategic acquisitions. Under his leadership, the company more than tripled in size. Previously, Mr. Kirk served as Chief Executive Officer of Hanger, Inc. from March 2008 to May 2012 and earlier as its Chief Operating Officer from January 2002 to February 2008. During his tenure, he drove revenue growth of more than 250% by increasing the number of patient care centers, introducing new musculoskeletal devices and services, and expanding core capabilities such as fabrication, distribution, and rehabilitation into scaled business segments. He also served as a member of Hanger's Board of Directors from January 2002 to November 2013. He has also held multiple leadership roles with the American Orthotic and Prosthetic Association, including serving in key committee and governance positions from 2002 to 2013. - Thomas F. Kirk， 2008年3月到2012年5月担任公司首席执行官；2002年1月到2011年9月担任公司总裁。2002年1月到2008年2月担任公司首席运营官。现任美国矫形器和假肢协会总裁，这是个志愿者职位。从1998年9月到2002年1月担任AlixPartners有限责任公司（前身是Jay Alix & Associates有限公司，一家管理咨询公司， Hanger 公司保留下来以促进其重组进程）主要负责人。从1997年5月到1998年8月担任FPL Group集团（位于美国佛罗里达州的一家提供全方位服务的能源供应商）规划、发展和质量副总裁。从1996年4月到1997年4月担任宾夕法尼亚州Quaker Chemical Corporation总裁和首席运营官。从1987年12月到1996年3月担任多个职位，最近的职位是担任Rhone Poulenc, S.A.新泽西州普林斯顿和法国巴黎区高级副总裁和首席财务官。从1977年3月到1988年11月在St. Joe Minerals Corp公司（Fluor Corporation公司的一个分部）工作。在此之前，他在Koppers Co有限公司担任多个销售、商业发展和工程职位。他持有美国匹兹堡大学战略规划/营销博士学位以及工商管理金融硕士学位。他还持有卡内基·梅隆大学机械工程学士学位。他是一名注册专业工程师和金融执行协会成员。
- Thomas F. Kirk has served as a member of Myomo, Inc.'s board of directors since September 2014 and as Lead Independent Director since October 2016. Mr. Kirk is a seasoned healthcare executive with extensive experience leading growth, operational transformation, and strategic expansion across medical services and device organizations. He most recently served as Chairman and Chief Executive Officer of American Medical Staffing, Inc. from 2013 to 2024, where he led the company's significant growth by expanding into additional clinical specialties, broadening its base of healthcare and rehabilitation customers, and executing on geographic expansion, third party reimbursement strategies, and strategic acquisitions. Under his leadership, the company more than tripled in size. Previously, Mr. Kirk served as Chief Executive Officer of Hanger, Inc. from March 2008 to May 2012 and earlier as its Chief Operating Officer from January 2002 to February 2008. During his tenure, he drove revenue growth of more than 250% by increasing the number of patient care centers, introducing new musculoskeletal devices and services, and expanding core capabilities such as fabrication, distribution, and rehabilitation into scaled business segments. He also served as a member of Hanger's Board of Directors from January 2002 to November 2013. He has also held multiple leadership roles with the American Orthotic and Prosthetic Association, including serving in key committee and governance positions from 2002 to 2013.
- Heather C. Getz
-
Heather C. Getz， 她是公共注册会计师。2010年1月，她被任命为高级副总裁和首席财务官；2009年5月，她加入BioTelemetry，担任财务部副总裁；2008年4月至2009年5月，她在Alita Pharmaceuticals（私营的专业制药公司）担任财务部副总裁，负责所有领域的金融、会计和信息系统；2002年3月至2008年4月，在加入Alita Pharmaceuticals之前，她在VIASYS Healthcare（医疗保健科技公司）担任过多个金融领导职位，包括指导公司的全球财务计划、预算和分析以及外部报告功能；1997年6月至2002年2月，她在Sunoco开始了她的职业生涯，担任着越来越重要的职务。她是公共注册会计师，获有维拉诺瓦大学会计学学士学位以及工商管理硕士学位。
Heather C. Getz has been a member of Myomo, Inc.'s board of directors since March 2024. She is the chair of the Audit Committee and member of the nomination and governance committee. Ms. Getz has over 25 years of experience in publicly traded healthcare and medical device companies where she created long term value through her financial and operational leadership. During her career, Heather has been integral in strategy development and successfully led the acquisition and/or integration of over 40 companies and secured over $1 billion in financing. Heather has also led several business restructurings removing hundreds of millions of costs from businesses while growing revenue. She was instrumental in turning around and growing BioTelemetry, Inc. from a market capitalization of $50 million to $2.8 billion upon its sale to Koninklijke Philips N.V. (NYSE: PHG) in 2021. Ms. Getz is an advisor and executive coach and also serves as a director and Chairman of the Audit Committee and member of the Compensation committee at Vital Connect, Inc. In August 2025, Ms. Getz retired as the Chief Financial and Operations Officer and Corporate Secretary of Butterfly Network, Inc. (NYSE: BFLY) a position she held since July 2023. Prior to that she was the Chief Financial Officer from May 2022 to July 2023. Previously, Ms. Getz served as Chief Financial Officer and President of North America at Healthy.io Ltd., a privately held medical technology company, from November 2021 to April 2022. Before joining Healthy.io Ltd., from May 2009 to November 2021, Ms. Getz held executive leadership positions at BioTelemetry, Inc., a publicly traded medical technology company, including serving as Chief Financial and Administrative Officer from January 2019 to July 2021, Chief Financial Officer from January 2010 to January 2019, and Vice President Finance from May 2009 to January 2010. Prior to BioTelemetry, Ms. Getz has also held various leadership positions at Alita Pharmaceuticals, VIASYS Healthcare Inc., and Sunoco, Inc. Ms. Getz received her undergraduate degree in Accountancy and a Master of Business Administration degree from Villanova University. - Heather C. Getz， 她是公共注册会计师。2010年1月，她被任命为高级副总裁和首席财务官；2009年5月，她加入BioTelemetry，担任财务部副总裁；2008年4月至2009年5月，她在Alita Pharmaceuticals（私营的专业制药公司）担任财务部副总裁，负责所有领域的金融、会计和信息系统；2002年3月至2008年4月，在加入Alita Pharmaceuticals之前，她在VIASYS Healthcare（医疗保健科技公司）担任过多个金融领导职位，包括指导公司的全球财务计划、预算和分析以及外部报告功能；1997年6月至2002年2月，她在Sunoco开始了她的职业生涯，担任着越来越重要的职务。她是公共注册会计师，获有维拉诺瓦大学会计学学士学位以及工商管理硕士学位。
- Heather C. Getz has been a member of Myomo, Inc.'s board of directors since March 2024. She is the chair of the Audit Committee and member of the nomination and governance committee. Ms. Getz has over 25 years of experience in publicly traded healthcare and medical device companies where she created long term value through her financial and operational leadership. During her career, Heather has been integral in strategy development and successfully led the acquisition and/or integration of over 40 companies and secured over $1 billion in financing. Heather has also led several business restructurings removing hundreds of millions of costs from businesses while growing revenue. She was instrumental in turning around and growing BioTelemetry, Inc. from a market capitalization of $50 million to $2.8 billion upon its sale to Koninklijke Philips N.V. (NYSE: PHG) in 2021. Ms. Getz is an advisor and executive coach and also serves as a director and Chairman of the Audit Committee and member of the Compensation committee at Vital Connect, Inc. In August 2025, Ms. Getz retired as the Chief Financial and Operations Officer and Corporate Secretary of Butterfly Network, Inc. (NYSE: BFLY) a position she held since July 2023. Prior to that she was the Chief Financial Officer from May 2022 to July 2023. Previously, Ms. Getz served as Chief Financial Officer and President of North America at Healthy.io Ltd., a privately held medical technology company, from November 2021 to April 2022. Before joining Healthy.io Ltd., from May 2009 to November 2021, Ms. Getz held executive leadership positions at BioTelemetry, Inc., a publicly traded medical technology company, including serving as Chief Financial and Administrative Officer from January 2019 to July 2021, Chief Financial Officer from January 2010 to January 2019, and Vice President Finance from May 2009 to January 2010. Prior to BioTelemetry, Ms. Getz has also held various leadership positions at Alita Pharmaceuticals, VIASYS Healthcare Inc., and Sunoco, Inc. Ms. Getz received her undergraduate degree in Accountancy and a Master of Business Administration degree from Villanova University.
高管简历
中英对照 | 中文 | 英文- Paul R. Gudonis
PaulR.Gudonis自2016年8月以来一直担任我们的董事会主席，自2011年7月以来担任我们的首席执行官兼董事。Gudonis先生也于2017年2月被任命为总裁。他的职业生涯横跨软件、电信、互联网服务和机器人领域。加入公司之前，Gudonis从2005年10月到2010年6月担任First Robotics总裁。在开始担任该职位之前，从2003年8月到2005年4月，Gudonis先生是Centra Software，Inc.的首席执行官。从2000年1月到2003年3月，Gudonis先生还担任Genuity，Inc.的首席执行官。他也曾担任马萨诸塞州高科技委员会主席，他是他的母校西北大学麦考密克工程学院院长顾问委员会的成员，在那里他获得了电气工程学位。在学校，他在生物医学工程系和NuVention医疗器械创新计划的顾问委员会任职。他还获得了Harvard University的工商管理硕士学位。
Paul R. Gudonis has been the Chairman of Myomo, Inc.'s board of directors since August 2016 and Myomo, Inc.'s Chief Executive Officer and a director of Myomo, Inc.'s company since July 2011. Mr. Gudonis was also appointed President in February 2017. During his tenure at Myomo, he has grown Myomo, Inc.'s operations, obtained reimbursement of the MyoPro by Medicare and other payers in the United States, and has expanded Myomo, Inc.'s business internationally. He has 40 years of experience in launching new technology based products and services to Myomo, Inc.'s company. His career spans the fields of software, telecommunications, internet services, and robotics. Prior to joining Myomo, Inc.'s company, Mr. Gudonis served as President at FIRST Robotics, or FIRST, from October 2005 until June 2010. Prior to his position at FIRST, Mr. Gudonis was the Chief Executive Officer of Centra Software, Inc., from August 2003 until April 2005. Mr. Gudonis was also the Chief Executive Officer of Genuity, Inc. from January 2000 until March 2003. He has also served as Chairman of the Massachusetts High Tech Council. Mr. Gudonis is a member of the Dean's Advisory Council at his alma mater, Northwestern University's McCormick School of Engineering, where he earned his degree in electrical engineering. At McCormick, he also serves on the industry advisory board of the Biomedical Engineering Department. He earned his MBA degree from Harvard University.- PaulR.Gudonis自2016年8月以来一直担任我们的董事会主席，自2011年7月以来担任我们的首席执行官兼董事。Gudonis先生也于2017年2月被任命为总裁。他的职业生涯横跨软件、电信、互联网服务和机器人领域。加入公司之前，Gudonis从2005年10月到2010年6月担任First Robotics总裁。在开始担任该职位之前，从2003年8月到2005年4月，Gudonis先生是Centra Software，Inc.的首席执行官。从2000年1月到2003年3月，Gudonis先生还担任Genuity，Inc.的首席执行官。他也曾担任马萨诸塞州高科技委员会主席，他是他的母校西北大学麦考密克工程学院院长顾问委员会的成员，在那里他获得了电气工程学位。在学校，他在生物医学工程系和NuVention医疗器械创新计划的顾问委员会任职。他还获得了Harvard University的工商管理硕士学位。
- Paul R. Gudonis has been the Chairman of Myomo, Inc.'s board of directors since August 2016 and Myomo, Inc.'s Chief Executive Officer and a director of Myomo, Inc.'s company since July 2011. Mr. Gudonis was also appointed President in February 2017. During his tenure at Myomo, he has grown Myomo, Inc.'s operations, obtained reimbursement of the MyoPro by Medicare and other payers in the United States, and has expanded Myomo, Inc.'s business internationally. He has 40 years of experience in launching new technology based products and services to Myomo, Inc.'s company. His career spans the fields of software, telecommunications, internet services, and robotics. Prior to joining Myomo, Inc.'s company, Mr. Gudonis served as President at FIRST Robotics, or FIRST, from October 2005 until June 2010. Prior to his position at FIRST, Mr. Gudonis was the Chief Executive Officer of Centra Software, Inc., from August 2003 until April 2005. Mr. Gudonis was also the Chief Executive Officer of Genuity, Inc. from January 2000 until March 2003. He has also served as Chairman of the Massachusetts High Tech Council. Mr. Gudonis is a member of the Dean's Advisory Council at his alma mater, Northwestern University's McCormick School of Engineering, where he earned his degree in electrical engineering. At McCormick, he also serves on the industry advisory board of the Biomedical Engineering Department. He earned his MBA degree from Harvard University.
- Micah J. Mitchell
Micah J. Mitchell自2018年7月起担任Myomo, Inc.的首席商务官。在加入Myomo, Inc.的公司之前，2016年6月至2018年12月，Mitchell先生曾担任耐用医疗设备制造商和分销商Invacare Corporation（纽约证券交易所代码：IVC）的副总裁，负责N.A.商业运营和业务发展。从2015年3月到2016年6月，他担任Numotion的区域副总裁，Numotion是一家私人控股的个人配置、医疗必需的移动产品和服务提供商。Micah是Wheelchair Vans，LLC的管理成员，这是一家轮椅无障碍货车租赁和销售业务，他于2011年12月开始运营，并一直运营到2015年6月。2008年至2012年，他在私人控股的定制轮椅企业Alliance Seating & Mobility担任销售总监。米切尔先生拥有得克萨斯大学奥斯汀分校McCombs商学院MBA学位和贝勒大学经济学学士学位。
Micah J. Mitchell served as Vice President, N.A. Commercial Operations and Business Development for Invacare Corporation (NYSE: IVC), a durable medical equipment manufacturer and distributor. From March 2015 to June 2016, he was a Regional Vice President for Numotion, a privately held provider of individually configured, medically necessary mobility products and services. Micah was the Managing Member for Wheelchair Vans, LLC, a wheelchair accessible van rental and sales business, which he started in December of 2011 and ran until June 2015. From 2008 to 2012, he served as Director of Sales at Alliance Seating & Mobility, a privately held custom wheelchair business. Mr. Mitchell has an MBA from the McCombs School of Business at the University of Texas at Austin and a BS in Economics from Baylor University.- Micah J. Mitchell自2018年7月起担任Myomo, Inc.的首席商务官。在加入Myomo, Inc.的公司之前，2016年6月至2018年12月，Mitchell先生曾担任耐用医疗设备制造商和分销商Invacare Corporation（纽约证券交易所代码：IVC）的副总裁，负责N.A.商业运营和业务发展。从2015年3月到2016年6月，他担任Numotion的区域副总裁，Numotion是一家私人控股的个人配置、医疗必需的移动产品和服务提供商。Micah是Wheelchair Vans，LLC的管理成员，这是一家轮椅无障碍货车租赁和销售业务，他于2011年12月开始运营，并一直运营到2015年6月。2008年至2012年，他在私人控股的定制轮椅企业Alliance Seating & Mobility担任销售总监。米切尔先生拥有得克萨斯大学奥斯汀分校McCombs商学院MBA学位和贝勒大学经济学学士学位。
- Micah J. Mitchell served as Vice President, N.A. Commercial Operations and Business Development for Invacare Corporation (NYSE: IVC), a durable medical equipment manufacturer and distributor. From March 2015 to June 2016, he was a Regional Vice President for Numotion, a privately held provider of individually configured, medically necessary mobility products and services. Micah was the Managing Member for Wheelchair Vans, LLC, a wheelchair accessible van rental and sales business, which he started in December of 2011 and ran until June 2015. From 2008 to 2012, he served as Director of Sales at Alliance Seating & Mobility, a privately held custom wheelchair business. Mr. Mitchell has an MBA from the McCombs School of Business at the University of Texas at Austin and a BS in Economics from Baylor University.
- Harry Kovelman
Harry Kovelman于2020年11月加入Myomo，担任首席医疗官。Kovelman博士在医疗器械和药品领域拥有25年的经验，其中包括从2017年4月至2020年10月担任Helius Medical技术的医疗事务高级副总裁，以及从2014年至2017年担任Pacira生物科学，Inc.（前身为Pacira Pharmaceuticals）的医疗事务副总裁。他还曾于2010年至2014年在Convatec Group Plc担任高级管理职务。他著有多篇关于康复程序的论文，并曾在众多关于医疗保健产品和服务的各种创新的专业会议上发表过演讲。他的职责包括领导创新产品的发布计划、KOL开发、创建科学平台、出版物策划以及与组织其他部分的跨职能工作，以确保为教育和临床目的向医疗保健专业人员、支付社区和患者适当和合规地传达科学和临床信息。Kovelman博士通过马里兰大学巴尔的摩大学医院的第五个路径项目获得了医学博士学位。他的本科工作在马里兰大学完成，获得心理学理学学士学位。
Harry Kovelman has 25 years of experience in medical devices and pharmaceuticals, including roles as Senior Vice President Medical Affairs for Helius Medical Technologies from April 2017 to October 2020 and Vice President, Medical Affairs for Pacira BioSciences, Inc. (formerly Pacira Pharmaceuticals) from 2014 2017. He also held a senior executive role at Convatec Group Plc from 2010 to 2014. He is the author of several papers on rehabilitation procedures and has presented at numerous professional conferences on various innovations in healthcare products and services. His responsibilities have included leading launch initiatives for innovative products, KOL development, creating scientific platforms, publication planning and working cross functionally with other parts of the organization to ensure the appropriate and compliant communication of scientific and clinical information to health care professionals, the payer community and patients for both educational and clinical purposes. Dr. Kovelman received his Doctor of Medicine degree through the fifth pathway program at University of Maryland, University Hospital in Baltimore Maryland. His undergraduate work was completed at the University of Maryland with a Bachelor of Science degree in psychology.- Harry Kovelman于2020年11月加入Myomo，担任首席医疗官。Kovelman博士在医疗器械和药品领域拥有25年的经验，其中包括从2017年4月至2020年10月担任Helius Medical技术的医疗事务高级副总裁，以及从2014年至2017年担任Pacira生物科学，Inc.（前身为Pacira Pharmaceuticals）的医疗事务副总裁。他还曾于2010年至2014年在Convatec Group Plc担任高级管理职务。他著有多篇关于康复程序的论文，并曾在众多关于医疗保健产品和服务的各种创新的专业会议上发表过演讲。他的职责包括领导创新产品的发布计划、KOL开发、创建科学平台、出版物策划以及与组织其他部分的跨职能工作，以确保为教育和临床目的向医疗保健专业人员、支付社区和患者适当和合规地传达科学和临床信息。Kovelman博士通过马里兰大学巴尔的摩大学医院的第五个路径项目获得了医学博士学位。他的本科工作在马里兰大学完成，获得心理学理学学士学位。
- Harry Kovelman has 25 years of experience in medical devices and pharmaceuticals, including roles as Senior Vice President Medical Affairs for Helius Medical Technologies from April 2017 to October 2020 and Vice President, Medical Affairs for Pacira BioSciences, Inc. (formerly Pacira Pharmaceuticals) from 2014 2017. He also held a senior executive role at Convatec Group Plc from 2010 to 2014. He is the author of several papers on rehabilitation procedures and has presented at numerous professional conferences on various innovations in healthcare products and services. His responsibilities have included leading launch initiatives for innovative products, KOL development, creating scientific platforms, publication planning and working cross functionally with other parts of the organization to ensure the appropriate and compliant communication of scientific and clinical information to health care professionals, the payer community and patients for both educational and clinical purposes. Dr. Kovelman received his Doctor of Medicine degree through the fifth pathway program at University of Maryland, University Hospital in Baltimore Maryland. His undergraduate work was completed at the University of Maryland with a Bachelor of Science degree in psychology.
- David A. Henry
David A. Henry， 在2014年5月担任执行副总裁，首席财务官和财务主管。2007年7月到2014年5月曾担任高级副总裁，首席财务官，财务主管。从2004年4月到2004年7月，他曾担任AMI控股股份有限公司（AMI半导体的母公司）的首席财务官。过去七年，2002年11月到2004年4月亨利先生在飞兆半导体国际公司担任全球业务的财务副总裁，从1997年3月至2002年11月担任企业控制官。1999年8月，他被任命为飞兆半导体国际公司的副总裁。
David A. Henry has over 35 years of financial, leadership and management experience in high technology manufacturing companies. From April 2004 to July 2007, he was Chief Financial Officer of AMI Semiconductor, a NASDAQ listed company. From July 2007 through June 2017, Mr. Henry was Chief Financial Officer of American Semiconductor Corporation, a NASDAQ listed company. From August 2017 until February 2019, he was Chief Financial Officer of Eos Energy Storage LLC, a then privately held company and manufacturer of grid scale energy systems for utilities and renewable project developers. Mr. Henry is a Certified Public Accountant (inactive). He earned his MBA from Santa Clara University and his BS in Business Administration from the University of California, Berkeley.- David A. Henry， 在2014年5月担任执行副总裁，首席财务官和财务主管。2007年7月到2014年5月曾担任高级副总裁，首席财务官，财务主管。从2004年4月到2004年7月，他曾担任AMI控股股份有限公司（AMI半导体的母公司）的首席财务官。过去七年，2002年11月到2004年4月亨利先生在飞兆半导体国际公司担任全球业务的财务副总裁，从1997年3月至2002年11月担任企业控制官。1999年8月，他被任命为飞兆半导体国际公司的副总裁。
- David A. Henry has over 35 years of financial, leadership and management experience in high technology manufacturing companies. From April 2004 to July 2007, he was Chief Financial Officer of AMI Semiconductor, a NASDAQ listed company. From July 2007 through June 2017, Mr. Henry was Chief Financial Officer of American Semiconductor Corporation, a NASDAQ listed company. From August 2017 until February 2019, he was Chief Financial Officer of Eos Energy Storage LLC, a then privately held company and manufacturer of grid scale energy systems for utilities and renewable project developers. Mr. Henry is a Certified Public Accountant (inactive). He earned his MBA from Santa Clara University and his BS in Business Administration from the University of California, Berkeley.